MTH-68/H oncolytic viral treatment in human high-grade gliomas
MTH-68/H oncolytic viral treatment in human high-grade gliomas
复制标题
DOI：
10.1023/b:neon.0000021735.85511.05
复制
发表时间：
2004-03-01
影响因子：
3.9
通讯作者：
Csatary, CM
中科院分区：
文献类型：
--
作者：
Csatary, LK;Gosztonyi, G;Csatary, CM
应用病毒疗法治疗人类肿瘤已有三十多年的历史。 MTH-68/H 是新城疫病毒的一种活减毒溶瘤病毒株，是用于治疗不同恶性肿瘤的病毒之一。在这里，我们报告了对多形性胶质母细胞瘤患者使用 MTH-68/H 的情况，多形性胶质母细胞瘤是最常见、最具侵袭性的神经外胚层肿瘤，预后不良，平均需要六个月到一年。 4例晚期高级别胶质瘤在常规抗肿瘤治疗失败后接受MTH-68/H治疗。这种治疗的存活率为 5-9 年，每位患者至今仍存活。尽管困难重重，每位患者都恢复了与以前相似的生活方式，并享受了良好的生活质量。这些患者中的每一位都多年来定期接受 MTH-68/H 作为唯一的肿瘤治疗形式，从未间断。
Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5-9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life. Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.